iifl-logo

Cupid Ltd Management Discussions

Add as a Preferred Source on Google
₹377.8
(-1.82%)
Nov 13, 2026|03:59:55 PM

Cupid Ltd Share Price Management Discussions

Economic overview and outlook
The global economy

The financial year 2025-26 unfolded against a global economy
that proved more resilient than many had feared, even as growth
remained modest and unevenly distributed. The International
Monetary Fund (IMF) estimated global growth at around 3.2% in
2025, easing to about 3.1% in 2026, with disinflation continuing
across most economies. The dominant theme of the year was
trade: a marked increase in tariffs and protectionist measures, and
the uncertainty they created, weighed on investment and external
demand in several regions. For an export-oriented business such
as ours, this backdrop reinforced the value of a geographically
diversified customer base and of long-standing institutional
relationships that are less sensitive to short-term cycles.

Currency movements were a further feature of the year. A generally
firmer US Dollar against the Indian Rupee supported the reported
realisations of exporters like us, although we remain conscious
that currency is a two-way risk that we manage through natural
hedging and pricing discipline.

The Indian economy

India once again stood out as the fastest-growing major economy
in the world. On the Ministry of Statistics and Programme
Implementations estimates, real GDP is estimated to have
grown by approximately 7.6% in FY2025-26, ahead of the
6.5% recorded in FY2024-25, supported by resilient domestic
consumption, sustained government capital expenditure and a
healthy investment climate. Growth was broad-based through the
year, with quarterly prints of 7.8% in the first quarter and 8.2%
in the second quarter of FY2025-26. International institutions
were similarly constructive: the IMF projected growth of 6.6% for
FY2025-26, the World Bank around 6.5%, and the Reserve Bank
of India progressively raised its own projection through the year.

Two domestic developments were particularly supportive of
consumption. First, inflation remained benign - the IMF expected
headline inflation to average below the 4% target during the
year - preserving household purchasing power. Second, the
rationalisation and simplification of the Goods and Services Tax
(GST), together with personal income-tax relief, is expected to put
more money in the hands of consumers and to support demand
for everyday products of the kind we are building in our consumer
business. Rural demand, which had lagged in prior years, showed
signs of a durable recovery. Taken together, this is a favourable
environment for both engines of our business: a stable, growing
home market for our consumer brands, and a competitive
manufacturing base from which to serve the world.

Sources: IMF World Economic Outlook and 2025 Article IV
Consultation (India); Ministry of Statistics and Programme
Implementation (MoSPI)/ Press Information Bureau; World Bank;
Reserve Bank of India.

Industry structure and developments

We operate across four related product families - male condoms,
female condoms, in-vitro diagnostic (IVD) test kits and water-
based lubricants -and, increasingly, a broader range of consumer
personal-care and wellness products. Each is underpinned by
attractive, structurally growing end-markets.

Condoms and sexual health

The global condom market continues to grow steadily, driven
by rising awareness of HIV and other sexually transmitted
infections, family-planning programmes and expanding retail and
e-commerce access. The global condom market is expected to
grow at a CAGR of about 8.7% between FY23-30. The Asia-Pacific
region is the largest market, accounting for roughly half of global
revenue, and latex remains the dominant material. As one of the
few fully integrated manufacturers supplying both public-health
programmes and private brands, we are well placed to participate
in this growth across geographies and channels.

The female condom - a specialised, high-value opportunity

The female condom is a distinct and strategically important
market. It is considerably smaller than the male condom market
- we estimate it at approximately 770 million in 2026, growing to
around 1.2 billion by 2030. As one of a handful of manufacturers
worldwide, and the holder of WFIO/UNFPA pre-qualification for our
natural-rubber-latex female condom, we occupy a rare position.
The market is increasingly segmenting by material - latex,
polyurethane and, at the premium end, nitrile - which is precisely
the direction in which we are investing (see Opportunities and
Operational review). Nitrile products typically command 25-35%
higher pricing than latex.

In-vitro diagnostics (IVD)

Rapid diagnostics remain a large and growing opportunity. In India,
IMARC estimated the IVD market at approximately US$5.3 billion
in 2024, growing to around US$10.0 billion by 2033. Structural
drivers include the rising incidence of chronic and infectious
disease, growing health awareness, the expansion of diagnostic
access into smaller towns and rural areas, and continued
government focus on public health. Our CE (EUIVDR) certifications,
obtained during the year for several of our kits, strengthen our
eligibility for regulated markets and institutional programmes.

FMCG and personal care in India

Indias fast-moving consumer goods (FMCG) sector is the
countrys fourth-largest, and one of its most dynamic. The India
Brand Equity Foundation estimated the market at approximately
US$289 billion in 2025 and expects it to grow to around US$643
billion by 2030, a CAGR of roughly 17%. Personal care and health-
a nd-well ness categories a re a mong the fastest-growi ng, su pported
by rising incomes, premiumisation, deeper rural penetration and
the rapid growth of modern trade and e-commerce. This is the
large, expanding home market into which we are extending our
manufacturing and quality credentials through a widening range
of consumer products.

Sources: Data Bridge Market Research (female condom market);
IMARC Group (India IVD); India Brand Equity Foundation, IBEF
(India FMCG).

Our business

Cupid Limited is a global healthcare, wellness and personal-care
company with a strong export foundation and a rapidly emerging
consumer platform. Incorporated in 1993 and listed on the BSE
(1995) and the NSE (2016), we were the first company in the world
to earn WFIO/UNFPA pre-qualification for both male and female
condoms - a credential that remains central to our institutional
business. From our manufacturing base in Maharashtra, we
supply condoms, diagnostic kits and lubricants to national health
programmes, multilateral agencies and brand owners in more
than 125 countries - working closely with global institutions
such as WFIO/UNFPA, PFSCM, the Global Fund, MSI, PSI and the
IDA Foundation - and a growing range of consumer products to
households in India and abroad.

We think of our business as running on two engines, powered
by one platform of manufacturing, research and quality. Our first
engine is our global, institutional B2B franchise - the anchor of
the business and the source of decades of credibility, regulatory
approvals and stability. Our second engine is a fast-scaling
B2C consumer business - condoms, lubricants, diagnostics
and a widening FMCG personal-care and wellness range - built
directly on top of that foundation. The consumer business is not
a replacement for exports; it is the scale engine that we expect,
over time, to grow beyond the core export business in size, while
exports continue to provide resilience. Both engines exist to serve
one purpose: to protect health and expand choice.

Opportunities and threats

Opportunities

- Premium nitrile female condoms. We have commenced
development of a latex-free nitrile (NBR) female condom for
aglobal market historically served by a single supplier. Nitrile
products typically command materially higher prices than
latex, and the segment carries high technical and regulatory
barriers to entry.

- Capacity expansion. Our new plant at Palava, with integrated
dual-polymer lines, is expected to lift capacity towards
approximately 1.25 billion male and 125 million female
condoms a year and to make us the only Indian manufacturer
across male, female and nitrile female condoms.

- Consumer and FMCG scale-up. A large and fast-growing
Indian FMCG market, combined with our manufacturing-
grade quality, allows us to build higher-margin consumer
brands, supported by distribution and retail partnerships.

- Regulated diagnostics. Our CE (EU IVDR) certifications open
regulated markets such as the European Economic Area and
strengthen eligibility for multilateral health tenders.

- Global tenders and institutional demand. A strong and
growing order pipeline across governments and UN agencies,
supported by our pre-qualification status and track record.

Threats and challenges

- Input-cost and crude-price volatility, which can affect the
cost of key raw materials.

- Currency movements, a tailwind in the current period but a
genuine two-way risk given our export weighting.

- Customer and tender concentration in the institutional
business, and the timing of large orders.

- Execution risk in commissioning new capacity, ramping the
nitrile programme and scaling a consumer business that
requires investment ahead of returns.

- Regulatory change across the many markets we serve, and
evolving quality and certification requirements.

Operational review and segment performance

FY2026 was the strongest operational year in our history. Demand was robust across both engines, and our long-standing quality
systems allowed us to scale output without compromising the electronic testing and inspection that define a Cupid product. The
indicative product-wise contribution to revenue is set out below and should be reconciled to the audited segment disclosures.

Product Mix

Primary engine

Male condoms

B2B + B2C

Female condoms

B2B (global)

New FMCG products

B2C (India)

IVD kits & lubricants

B2B + B2C

Male condoms

Our flagship category and the foundation of the business, serving three routes to market - international tenders and public-health
programmes, OEM and private-label supply, and our own consumer brands. Volumes grew strongly during the year across both
institutional and domestic channels.

Female condoms

A category in which we hold a rare global position. Our WHO/UNFPA-prequalified natural-rubber-latex female condom is supplied to
more than 50 countries, and during the year we began developing a premium nitrile variant to address the higher-value end of this
market.

FMCG - personal care and wellness

The fastest-scaling part of our portfolio, launched in FY2024, this consumer range now spans fragrances, personal care and home
hygiene under brands such as Cupid Angel, Cupi Safe, CupiKIT, CupiSURE, NiVi and LiVi Flome, and is made with the same rigorous
processes that earned our global certifications - quality being the bridge from our institutional heritage to the Indian shelf. During the
year we launched a range of new products, including flavoured and dotted condoms, face washes, talcum powder, sunscreen, shower
gels, body mists, hand washes and colour cosmetics.

Distribution deepened materially. Our FMCG products are now available across more than 1.5 lakh (150,000) retail outlets nationwide
- spanning chemists (over 75,000 outlets), cosmetics (over 47,000), groceries, pan-plus and open-format stores - supported by a
growing modern-trade presence (over 2,900 stores listed, and more than 4,000 targeted for FY2027) and an e-commerce channel that
serviced over 52,000 orders. Our strategic investment in Baazar Style Retail is expected to accelerate this reach further.

IVD kits and lubricants

A growing range of rapid diagnostic test kits - including pregnancy, HIV 1&2, Hepatitis B, Syphilis, malaria, dengue and COVID-19
antigen tests - alongside water-based lubricant sachets. CE (EU IVDR) certification secured during the year opens regulated markets
for several kits.

Exports and geographic mix

Exports remained the anchor of our revenue. In FY2026 we exported to more than 125 countries, with exports of Rs 208.13 Or
representing approximately 59.3% of revenue from operations, and a particularly strong presence across Africa. The balance was
contributed by our growing domestic business. Our institutional order pipeline across government and UN-agency programmes is the
strongest it has been.

Manufacturing, capacity and supply security

Our established facility at Sinnar, near Nashik, operates to GMP-compliant quality-management systems designed to satisfy drug-
regulatory agencies worldwide, with every condom electronically tested before dispatch. Our principal growth investment is the new plant
at Palava, purpose-built with integrated dual-polymer dipping for both natural-rubber-latex and nitrile products. On full commissioning,
total capacity is expected to rise towards approximately 1.25 billion male and 125 million female condoms a year. We manage input
costs deliberately, holding raw-material inventory - including crude-linked inputs -comfortably for well over six months, which supports
uninterrupted execution and margin resilience.

Financial performance and analysis

In FY2026 we delivered the strongest financial performance in our history, comfortably ahead of the guidance of Rs 335 Cr of revenue
and Rs 100 Cr of profit that we had set at the start of the year. The summarised consolidated results for the last three financial years
are set out below.

Rs Crore (consolidated)

FY2026 FY2025 FY2024 YoY

Revenue from operations

357.71 183.52 171.09 +94.9%

Other income

33.69 19.66 7.22

Total income

391.40 203.18 178.30 +92.6%

EBITDA

116.70 41.73 50.10 +179.7%

Profit before tax

142.47 54.86 52.58 +159.7%

Profit after tax

108.23 40.89 39.85 +164.7%

EPS (Rs adjusted for bonus)

0.81 0.30 0.29 +170%

Results of operations

Total income rose 93% to Rs 391.40 Cr and revenue from operations grew 95% to Rs 357.71 Cr, reflecting broad-based volume growth
across both our export and domestic businesses and a richer product mix. Importantly, this growth was highly profitable. EBITDA
increased 180% to Rs 116.70 Cr and profit before tax 160% to Rs 142.47 Cr, as the operating leverage inherent in our model came
through: as volumes scaled, our cost base grew far more slowly, and a favourable export-realisation environment supported margins.
Profit after tax increased 165% to Rs 108.23 Cr, and earnings per share (adjusted for the bonus issue) rose to Rs 0.81 from Rs 0.30.

The scale of the step-up is best seen against the prior two years. After a period of consolidation in FY2025 - when EBITDA ofRs 41.73
Cr was in fact below the Rs 50.10 Cr of FY2024, as margins compressed - FY2026 marked a decisive breakout on both revenue and
profitability. Our operating profit (EBITDA) margin on revenue from operations expanded to approximately 32.6% (FY2025: 22.7%) and
our net profit margin to approximately 30.3% (FY2025: 22.3%), driven by operating leverage, a favourable currency environment and
disciplined cost management.

The fourth quarter was the strongest in our history and encapsulated the years momentum. Q4 FY2026 revenue from operations rose
112% year on year to Rs 119.96 Cr and total income 116% to Rs 132.04 Cr; EBITDA increased 180% to Rs 37.52 Cr (a margin of 31.3%),
profit before tax 197% to Rs 47.45 Cr, and profit aftertax 215% to Rs 36.26 Cr (a margin of 30.3%). We expect margins to remain healthy
as scale builds, while noting that quarter-to-quarter mix and the timing of large institutional orders can cause variability.

Financial position

Our balance sheet remained a source of strength. Total assets grew to Rs 553.22 Cr (FY2025: Rs 371.78 Cr) and total equity to Rs 450.81
Cr (FY2025: Rs 342.19 Cr). We carry only modest borrowings - total borrowings of approximately Rs 51.0 Cr at the year-end, for a debt-
to-equity ratio of just 0.11 times - and we ended the year in a strong net-cash position, with cash and bank balances ofRs 186.45 Cr
comfortably exceeding total debt. This affords us both resilience and the flexibility to invest in growth.

During the year we deployed capital towards our new manufacturing capacity at Palava and made strategic investments reflected in
a rise in non-current investments to Rs 74.65 Cr (FY2025: Rs 15.66 Cr). Further, a total commitment ofRs 331.53 Cr has been made to
Baazar Style Retail Limited, out of which Rs 82.88 Cr and Rs 36.93 Cr were deployed in April 2026 and May 2026, respectively, pursuant
to the conversion of 15 lakh convertible warrants in May 2026, out of the total 1.01 Cr convertible warrants to accelerate our consumer
distribution reach, alongside an investment in the Gil Flealthcare Fund. We also carried higher inventoryRs 70.04 Cr, reflecting more
than six months of raw-material cover held to protect against input-cost volatility and to ensure uninterrupted execution. Our capital
allocation philosophy remains opportunistic, disciplined and value-driven: we evaluate each opportunity on its merits and expected
returns.

Reflecting a stronger balance sheet and our confidence in the outlook, the promoter share-pledge was reduced to 34.26% during the
year.

Equity, bonus issue and shareholding

During FY2026 we rewarded shareholders with a 4:1 bonus issue, following which the equity share capital stood at Rs 134.47 Cr,
comprising 1,34,46,60,700 equity shares of face value Rs 1 each (all per-share figures in this discussion are adjusted for the bonus). As
on 31 March 2026, the promoter and promoter group held approximately 46.03% of the equity and the public 53.97%. As on 15 May
2026, the Companys market capitalisation was approximatelyRs 16,301 Cr.

Key financial ratios

In accordance with the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the key financial ratios are set out
below, with explanations provided for those that changed by 25% or more, reflecting the scale-up of the business during the year.

Ratio

FY2026 FY2025 Variance Change / explanation

Inventory Turnover

2.65 1.83 45.01 Primarily due to growth in sales and improved movement
of Inventory.

Interest Coverage Ratio

51.75 27.74 86.58 Increase due to Higher Profitability.

Current Ratio

4.67 13.30 (64.91) Due to Long term strategic investment & Capex
Investment.

Debt Equity Ratio

0.09 0.04 133.15 The group is using a moderate level of borrowed funds to
finance operations and assets.

Operating Profit Margin (%)

32.63 22.74 43.49 Due to Better Product mix and cost efficiency.

Net Profit Margin (%)

30.26 22.28 35.81 Due to Better Product mix and cost efficiency.

Outlook

We enter FY2027 with our strongest-ever order pipeline, an expanding FMCG distribution network, growing international opportunities
and significant new capacity coming on stream. Our strategy is to keep building a diversified global wellness, personal-care and
healthcare platform - combining global B2B leadership with scalable consumer-facing brands, in India and abroad. Against this
backdrop, we have set the following medium-term targets.

Financial year

Revenue target (Rs Cr) Net profit target (Rs Cr)

FY2027

725-750 210-225

FY2028

1,085 304

FY2029

1,500 450

These objectives rest on tangible drivers: continued expansion of global exports and institutional business; rapid scaling of our
FMCG and consumer wellness and healthcare brands; capacity expansion to support higher volumes and new categories; strategic
investments and distribution partnerships that accelerate market access; and the operating leverage that scale brings. We believe our
combination of manufacturing excellence, global certifications, a strong net-cash balance sheet and a disciplined approach to capital
allocation positions us well to create durable, long-term value for shareholders.

Risks, concerns and their management

We operate a formal risk-management framework, overseen by the Board through its Risk Management and Audit Committees, which
seeks to identify, assess and mitigate the principal risks to our business. The principal risks, and how we manage them, are summarised
below.

- Input-cost / crude-price volatility - mitigated by holding more than six months of raw-material cover and by inflation-linked price
revisions.

- Currency movement - a tailwind in the current period but a two-way risk, managed through natural hedging and pricing.

- Customer / tender concentration - addressed through diversification across geographies and channels and the growth of our
domestic business.

- Execution of the Palava ramp-up and nitrile programme - managed through phased commissioning and our established
manufacturing discipline.

- Integration of strategic investments - managed through staged deployment and active monitoring of the Baazar Style Retail and
Gil Flealthcare Fund investments.

- Regulatory change across markets - mitigated by an embedded quality-and-compliance culture and a broad certification base.
Internal control systems and their adequacy

We maintain internal control systems that we believe are adequate for the size, scale and nature of our operations, and commensurate
with the requirements of the Companies Act, 2013. These systems are designed to provide reasonable assurance regarding the
reliability of financial reporting, the safeguarding of assets, the prevention and detection of fraud and error, compliance with applicable
laws and regulations, and the orderly and efficient conduct of business. Our processes are supported by defined authority levels,
standard operating procedures and periodic review.

Our internal control systems are reviewed by an internal audit function, whose observations and the adequacy of controls are periodically
reviewed by the Audit Committee of the Board. During the year, no material weaknesses in the design or operation of internal controls
were observed. The Audit Committee was reconstituted during the year and comprises independent directors, consistent with our
commitment to strong governance.

Human resources and industrial relations

Our people are central to our ability to manufacture intimate, life-protecting products to exacting global standards. We seek to attract
and retain skilled talent across manufacturing, quality, research, sales and support functions, and to invest in training and safe working
practices in our GMP-grade facilities. The operating leverage in our model is visible in our people costs: employee costs ofRs 31.82 Cr
in FY2026 represented roughly 9% of revenue from operations, down from around 16% in the prior year, even as output scaled sharply
- reflecting the productivity of our workforce. Industrial relations remained cordial throughout the year.

Cautionary statement

Statements in this Management Discussion and Analysis that describe our objectives, projections, estimates, expectations or
predictions may be forward-looking statements within the meaning of applicable securities laws and regulations. These statements
are based on certain assumptions and expectations of future events, and actual results could differ materially from those expressed or
implied. Important factors that could cause a difference include economic and political conditions in India and the markets in which we
operate, movements in raw-material prices and currency exchange rates, changes in government regulation, tax laws and other statutes,
demand and pricing in our markets, the timing of large institutional orders, and other incidental factors. We undertake no obligation to
publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2026, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited. All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132 (Member ID - NSE: 10975 BSE: 179 MCX: 55995 NCDEX: 01249), DP SEBI Reg. No. IN-DP-185-2016, Merchant Banker SEBI Regn. No. INM000010940, RA SEBI Regn. No: INH000000248, BSE Enlistment Number (RA): 5016, AMFI-Registered Mutual Fund Distributor & SIF Distributor
ARN NO : 47791 (Date of initial registration – 17/02/2007; Current validity of ARN – 08/02/2027), PFRDA Reg. No. PoP 20092018, IRDAI Corporate Agent (Composite) : CA1099

ISO certification icon
We are ISO/IEC 27001:2022 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.